IDEAS home Printed from https://ideas.repec.org/a/spr/ariqol/v14y2019i5d10.1007_s11482-018-9654-8.html
   My bibliography  Save this article

Quality of Life Outcomes in Internet-Delivered (Space from Depression) Treatment for Depression

Author

Listed:
  • A. Enrique

    (SilverCloud Health
    University of Dublin, Trinity College)

  • J. Burke

    (SilverCloud Health
    University of Dublin, Trinity College)

  • D. Richards

    (SilverCloud Health
    University of Dublin, Trinity College)

  • L. Timulak

    (University of Dublin, Trinity College)

Abstract

Quality of Life (QoL) outcomes in interventions for depression are an area in the literature that has received little focus, particularly in trials relating to internet-delivered psychological interventions. Evaluating QoL outcomes are necessary to more completely understand if an intervention is successful in the treatment of depression, given that a decrease in negative symptoms in depression does not equate to synonymous increase in QoL. This secondary analysis study is aimed to examine the effects of an internet-delivered intervention for a mild to moderate depressed sample on QoL. 188 participants were randomly allocated to the Space from Depression intervention (n = 96) or a waiting-list group (n = 92). The intervention is an eight-module online cognitive-behavioural therapy intervention for depression. The trial had a duration of 8 weeks and the results were explored up to 3 months later. QoL was measured using the EuroQol-5D (EQ-5D) at different time points. The intervention produced positive effects in the global scores of QoL at post-treatment an these results were maintained at follow-up, although no differences between conditions were found. Analyses of the QoL dimensions showed a significant improvement on the Anxiety/depression dimension compared to controls, but no effects were found in other dimensions. The results suggest that internet-delivered interventions has the potential to produce changes in QoL. These results can potentially be understood by the lower impairments within a mild to moderate depressed sample. Further inferences about the sensitivity of the EQ-5D measure within this population are discussed in light of the findings.

Suggested Citation

  • A. Enrique & J. Burke & D. Richards & L. Timulak, 2019. "Quality of Life Outcomes in Internet-Delivered (Space from Depression) Treatment for Depression," Applied Research in Quality of Life, Springer;International Society for Quality-of-Life Studies, vol. 14(5), pages 1301-1313, November.
  • Handle: RePEc:spr:ariqol:v:14:y:2019:i:5:d:10.1007_s11482-018-9654-8
    DOI: 10.1007/s11482-018-9654-8
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s11482-018-9654-8
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.

    File URL: https://libkey.io/10.1007/s11482-018-9654-8?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. M. C. Angermeyer & A. Holzinger & H. Matschinger & K. Stengler-Wenzke, 2002. "Depression and Quality of Life: Results of a Follow-Up Study," International Journal of Social Psychiatry, , vol. 48(3), pages 189-199, September.
    2. Paul Kind & Geoffrey Hardman & Susan Macran, 1999. "UK population norms for EQ-5D," Working Papers 172chedp, Centre for Health Economics, University of York.
    3. Paul Dolan & Claire Gudex & Paul Kind & Alan Williams, 1995. "A social tariff for EuroQol: results from a UK general population survey," Working Papers 138chedp, Centre for Health Economics, University of York.
    4. David Parkin & Nigel Rice & Nancy Devlin, 2010. "Statistical Analysis of EQ-5D Profiles: Does the Use of Value Sets Bias Inference?," Medical Decision Making, , vol. 30(5), pages 556-565, September.
    5. Devlin, N. & Parkin, D. & Browne, J., 2009. "Using the EQ-5D as a performance measurement tool in the NHS," Working Papers 09/03, Department of Economics, City University London.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Laura Bojke & Edward Hornby & Mark Sculpher, 2007. "A Comparison of the Cost Effectiveness of Pharmacotherapy or Surgery (Laparoscopic Fundoplication) in the Treatment of GORD," PharmacoEconomics, Springer, vol. 25(10), pages 829-841, October.
    2. Bishal Mohindru & David Turner & Tracey Sach & Diana Bilton & Siobhan Carr & Olga Archangelidi & Arjun Bhadhuri & Jennifer A. Whitty, 2020. "Health State Utility Data in Cystic Fibrosis: A Systematic Review," PharmacoEconomics - Open, Springer, vol. 4(1), pages 13-25, March.
    3. Dina Jankovic & Pedro Saramago Goncalves & Lina Gega & David Marshall & Kath Wright & Meena Hafidh & Rachel Churchill & Laura Bojke, 2022. "Cost Effectiveness of Digital Interventions for Generalised Anxiety Disorder: A Model-Based Analysis," PharmacoEconomics - Open, Springer, vol. 6(3), pages 377-388, May.
    4. Gisela Kobelt & J. Berg & P. Lindgren, 2006. "Costs and quality of life in multiple sclerosis in The Netherlands," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 7(02), pages 55-64, July.
    5. Billingsley Kaambwa & Julie Ratcliffe, 2018. "Predicting EuroQoL 5 Dimensions 5 Levels (EQ-5D-5L) Utilities from Older People’s Quality of Life Brief Questionnaire (OPQoL-Brief) Scores," The Patient: Patient-Centered Outcomes Research, Springer;International Academy of Health Preference Research, vol. 11(1), pages 39-54, February.
    6. Carsten Hirt & Sergio Iannazzo & Silvia Chiroli & Lisa J. McGarry & Philipp Coutre & Leif Stenke & Torsten Dahlén & Jeffrey H. Lipton, 2019. "Cost Effectiveness of the Third-Generation Tyrosine Kinase Inhibitor (TKI) Ponatinib, vs. Second-Generation TKIs or Stem Cell Transplant, as Third-Line Treatment for Chronic-Phase Chronic Myeloid Leuk," Applied Health Economics and Health Policy, Springer, vol. 17(4), pages 555-567, August.
    7. Billingsley Kaambwa & Gang Chen & Julie Ratcliffe & Angelo Iezzi & Aimee Maxwell & Jeff Richardson, 2017. "Mapping Between the Sydney Asthma Quality of Life Questionnaire (AQLQ-S) and Five Multi-Attribute Utility Instruments (MAUIs)," PharmacoEconomics, Springer, vol. 35(1), pages 111-124, January.
    8. Donna Rowen & John Brazier & Clara Mukuria & Anju Keetharuth & Arne Risa Hole & Aki Tsuchiya & Sophie Whyte & Phil Shackley, 2016. "Eliciting Societal Preferences for Weighting QALYs for Burden of Illness and End of Life," Medical Decision Making, , vol. 36(2), pages 210-222, February.
    9. Emma McIntosh, 2006. "Using Discrete Choice Experiments within a Cost-Benefit Analysis Framework," PharmacoEconomics, Springer, vol. 24(9), pages 855-868, September.
    10. Lieven Annemans & Mélanie Brignone & Sylvain Druais & Ann Pauw & Aline Gauthier & Koen Demyttenaere, 2014. "Cost-Effectiveness Analysis of Pharmaceutical Treatment Options in the First-Line Management of Major Depressive Disorder in Belgium," PharmacoEconomics, Springer, vol. 32(5), pages 479-493, May.
    11. Gisela Kobelt & J. Berg & P. Lindgren & G. Izquierdo & O. Sánchez-Soliño & J. Pérez-Miranda & M. Casado, 2006. "Costs and quality of life of multiple sclerosis in Spain," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 7(2), pages 65-74, July.
    12. José Nunes, 1998. "Economic evaluation of rehabilitation: The quality of life approach using EuroQol," International Advances in Economic Research, Springer;International Atlantic Economic Society, vol. 4(2), pages 192-201, May.
    13. Stefano Capri, 2013. "The economics of orphan drugs: the case of osteosarcoma treatment," LIUC Papers in Economics 265, Cattaneo University (LIUC).
    14. Brazier, John & Roberts, Jennifer & Deverill, Mark, 2002. "The estimation of a preference-based measure of health from the SF-36," Journal of Health Economics, Elsevier, vol. 21(2), pages 271-292, March.
    15. Lena Lundberg & Magnus Johannesson & Dag G.L. Isacson & Lars Borgquist, 1999. "The Relationship between Health-state Utilities and the SF-12 in a General Population," Medical Decision Making, , vol. 19(2), pages 128-140, April.
    16. Miqdad Asaria & Susan Griffin & Richard Cookson, 2013. "Distributional cost-effectiveness analysis: a tutorial," Working Papers 092cherp, Centre for Health Economics, University of York.
    17. Ya-Chen Shih & Nebiyou Bekele & Ying Xu, 2007. "Use of Bayesian Net Benefit Regression Model to Examine the Impact of Generic Drug Entry on the Cost Effectiveness of Selective Serotonin Reuptake Inhibitors in Elderly Depressed Patients," PharmacoEconomics, Springer, vol. 25(10), pages 843-862, October.
    18. Manuel B. Huber & Julia Felix & Martin Vogelmann & Reiner Leidl, 2017. "Health-Related Quality of Life of the General German Population in 2015: Results from the EQ-5D-5L," IJERPH, MDPI, vol. 14(4), pages 1-12, April.
    19. Tianxin Pan & Brendan Mulhern & Rosalie Viney & Richard Norman & Janel Hanmer & Nancy Devlin, 2022. "A Comparison of PROPr and EQ-5D-5L Value Sets," PharmacoEconomics, Springer, vol. 40(3), pages 297-307, March.
    20. Garry Barton & Tracey Sach & Michael Doherty & Anthony Avery & Claire Jenkinson & Kenneth Muir, 2008. "An assessment of the discriminative ability of the EQ-5D index , SF-6D, and EQ VAS, using sociodemographic factors and clinical conditions," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 9(3), pages 237-249, August.

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:ariqol:v:14:y:2019:i:5:d:10.1007_s11482-018-9654-8. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.